Quarterly report pursuant to Section 13 or 15(d)

Note Payable - Additional Information (Detail)

v2.4.0.8
Note Payable - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2014
Jun. 30, 2014
Sep. 30, 2013
Apr. 19, 2013
Note Payable [Line Items]        
Notes Payable, Total     $ 944,707  
Adjustments to Additional Paid in Capital, Warrant Issued     55,293  
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 0.75
Interest Expense, Debt 2,765 8,294    
Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001 $ 0.001  
Warrant
       
Note Payable [Line Items]        
Fair Value Assumptions, Risk Free Interest Rate     2.64%  
Fair Value Assumptions, Expected Dividend Rate     0.00%  
Fair Value Assumptions, Expected Term     10 years  
Fair Value Assumptions, Expected Volatility Rate     114.00%  
Common Stock, Par or Stated Value Per Share     $ 0.034  
Massachusetts Life Sciences Center
       
Note Payable [Line Items]        
Subordinated Debt     $ 1,000,000  
Debt Instrument, Payment Terms     The loan bears interest at a rate of 10% per annum, and will become fully due and payable on the earlier of (i) September 30, 2018, (ii) the occurrence of an event of default under the MLSC Loan Agreement, or (iii) the completion of a sale of substantially all of our assets, a change-of-control transaction or one or more financing transactions in which the Company receives net proceeds of $5,000,000 or more in a 12-month period.  
Warrants Issued To Purchase Of Common Stock     145,985  
Class Of Warrant Or Right Expiration Date     Sep. 30, 2023  
Class of Warrant or Right, Exercise Price of Warrants or Rights     $ 0.274